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Abstract
Background: Despite the high prevalence of genotype 1b hepatitis C virus (HCV) among patients, a cell culture
system that permits entire viral life cycle of genotype 1b isolates is limited. To develop a cell-cultured hepatitis C virus
(HCVcc) of genotype 1b, the proper combination of HCV genomic variants and host cells is essential. HCV genomes
isolated from patients with distinctive symptoms may provide the variants required to establish an HCVcc of genotype 1b.
Results: We first established subgenomic replicons in Huh7 cells using HCV cDNAs isolated from two patients: one
with fulminant hepatitis after liver transplantation (TPF1) and another with acute hepatitis and moderate symptoms
(sAH). Replicons established from TPF1 and sAH showed mutations in NS4B and in NS3 and NS5A, respectively. Using
these replication machineries, we constructed HCV genomic RNAs for each isolate. Virus infectivity was evaluated by
a focus-forming assay, which is dependent on the intracellular expression of core antigen, and production of virus
particles was assessed by density-gradient centrifugation. Infectious virus was only observed in the culture medium of
cells transfected with TFP1 HCV RNA. A chimeric genome with the structural segment (5′-untranslated region [UTR]
through NS2) from sAH and the replication machinery (NS3 through 3′-UTR) from TPF1 exhibited greater infectivity
than did TFP1, despite formation of deficient virus particles in sAH, suggesting that this genomic segment potentiates
virus particle formation. To identify the responsible variants, infectious virus formation was assessed in a chimeric
genome carrying parts of the sAH structural segment of the TPF1 genome. A variant in NS2 (M170T) was identified
that enhanced infectious virus formation. HCVcc carrying an NS2 gene encoding the M170T substitution and adaptive
mutations in NS4B (referred to as TPF1-M170T) infected naïve cured Huh7 cells in a CD81-dependent manner.
Conclusions: We established a novel HCVcc of genotype 1b in Huh7 cells by introducing an amino acid variant
in NS2 and adaptive mutations in NS4B from HCV genomic RNA isolated from a patient with fulminant HCV after
liver transplantation.
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Background
The hepatitis C virus (HCV) chronically infects approxi-
mately 130–150 million people annually worldwide, and
350,000–500,000 deaths every year are attributed to HCV–
related liver diseases (World Health Organization web site,
2015: http://www.who.int/mediacentre/factsheets/fs164/en/).
The genome of HCV, which belongs to the Flaviviridae fam-
ily, comprises single-stranded RNA of about 9.6 kb consisting
of untranslated regions (UTRs) at each end and a long open
reading frame (ORF). The ORF is translated from an internal
ribosome entry site (IRES) to generate structural (core, E1
and E2) and non-structural (p7, NS2, NS3, NS4A, NS4B,
NS5A, and NS5B) proteins [1]. HCV has been classified into
seven major genotypes and several subtypes. In particular,
genotype 1 (subtypes 1a and 1b) is responsible for the major-
ity of known HCV infections and is resistant to pegylated
interferon (PEG-IFN) and ribavirin (RBV) therapy [2,
3]. In Japan, triple-combination therapy for chronic
HCV involving protease inhibitors and PEG-IFN/RBV
has been approved for treatment of infections with
the major HCV subtype (1b) since 2011.
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The establishment of HCV subgenomic replicons was
an important advancement for virological HCV research,
leading to the development of direct-acting antiviral
drugs [4]. This in turn resulted in a second major break-
through with the establishment of cell-cultured HCV
(HCVcc) from an HCV clone (JFH-1) isolated from a
patient with fulminant hepatitis C [5]. The JFH-1 HCVcc
was shown to infect Huh7 cells in a CD81-dependent
manner, and could self-replicate using its own NS5B
RNA-dependent RNA polymerase (RdRp). HCVcc com-
pletes its entire life cycle in vitro, and chimeric HCVcc
strains harboring structural segments (the core through
NS2) from the HCV genomes of all seven genotypes and
the JFH-1 replicon have been developed [5–10].
Adaptive mutations that improve the efficiency of viral
replication have been identified in replication systems
using these subgenomic replicons and HCVcc strains
[11–17]. Mutations located between the NS3 and NS5A
proteins mostly enhance the replication of genomic
RNA. In addition to these mutations in the viral genome,
mutations in host cells, such as those found in Huh7.5
cells, which are Huh7 cells that have had the subgenomic
replicons removed by IFN treatment, show great impacts
on not only genomic replication but also infectious virus
formation [7, 15, 18].
The use of HCVcc has enabled the identification of
mutations in the p7 and NS2 proteins, which affect the
assembly of infectious virus [14, 19]. The effects of these
mutations were also shown to be enhanced by other mu-
tations in NS3 and NS5A, suggesting cross-talk between
these HCV proteins [13, 14, 16, 17]. The p7 and NS2
proteins are indispensable for infectious virus formation
in trans-packaging systems as well as HCVcc [20]. The
direct or indirect interaction of these proteins with
structural proteins such as the capsid protein, core, and
membrane proteins E1/E2 was suggested by their sub-
cellular localization [21–23]. In addition, compensatory
mutations for virus assembly defects caused by mutations
in the core protein were identified in p7 and NS2 [24].
Combinations and applications of these variants has
improved the development of HCVcc using JFH-1 and
Huh7.5 cells, and has helped to establish HCVcc genotypes
1a, 2a, 2b, and 3a [25–30]. Although subgenomic replicons
of genotype 1b were established at an early stage in HCV
research, no robust HCVcc genotype 1b has been reported
to date because of interference with virus particle forma-
tion by the adapted mutations in the replicons [31, 32]. As
described above, the genomic context, i.e., the combination
of variants, including adaptive mutations in the genome, is
an important consideration for virus replication. Therefore,
we hypothesized that the proper combination of variants
in genotype 1b would enable successful establishment of
an HCVcc of genotype 1b. In this study, we isolated HCV
cDNA from two patients infected with genotype 1b HCV
and identified the variants that would best allow for repli-
cation of genotype 1b HCVcc in Huh7 cells.
Methods
Ethics Statement
This study was approved by the ethical committee of
Shinshu University School of Medicine, Matsumoto,
Japan, and written informed consent was obtained from
all patients. The study was conducted in accordance
with the principles of the Declaration of Helsinki.
Cell culture
The human hepatocarcinoma cell line Huh7 (JCRB0403)
and Huh7-derived cured cells were cultured in 5 % CO2
at 37 °C in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10 % fetal bovine serum, 50 U/mL
penicillin, and 50 μg/mL streptomycin.
Cloning of HCV cDNA
Serum specimens were obtained from patients at Shinshu
University Hospital. Total RNA was recovered from the
samples using the High Pure Viral RNA kit (Roche) ac-
cording to the manufacturer’s instructions. HCV cDNA
was amplified by long-distance RT-PCR as described pre-
viously [33–35]. HCV cDNA was synthesized using Super-
script II reverse transcriptase (Invitrogen) with the XR58R
primer. After RNase H (Takara) treatment at 37 °C, the
cDNA mixture was amplified by PCR with LA Taq DNA
polymerase (Takara) and the HC-Long A1 and 1b5290AS
primers, or the HC4498S and 1b9405R primers for
30 cycles of denaturation at 94 °C for 20 s and extension
at 68 °C for 5 min. A second-round PCR was performed
with the HC85F and 1b5290AS primers or the HC4888F
and HC9302R primers for 20 cycles under the same
conditions as the first-round PCR. The PCR products were
purified from the gel using the QIA-quick gel extraction
kit (QIAGEN), and were then cloned into the pGEM-T
Easy vector (Promega). The cDNA clones TPF1-0153
and TPF1-4893 were amplified from serum samples
from patient TPF1, and sAH-0153 and sAH-4893 were
obtained from serum samples from patient sAH.
Four clones of each fragment were sequenced with a
CEQ-2000XL DNA analysis system (Beckman Coulter)
with a DTCS quick start kit and HCV-specific primers
according to the manufacturer’s instructions. Sequence data
were analyzed with Sequencher (Gene Codes Corporation)
and MacVector (MacVector, Inc.) software packages.
HCV cDNA of the 5′UTR was obtained by 5′ rapid
amplification of cDNA ends (RACE), which was carried
out using a 5′RACE System (v. 2.0; Invitrogen) accord-
ing to the manufacturer’s instructions. HCV RNA was
reverse-transcribed from serum samples with the chiba-
AS primer and subjected to a TdT-tailing reaction. PCR
was carried out with the 5′RACE Abridged Anchor
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primer and the KY78 primer. A second-round PCR was
carried out with the Universal Amplification and KM2
primers, and cloned into the pGEM-T easy vector. HCV
cDNA clones containing the nucleotides 1–709 were
designated TPF1-0007 and sAH-0007.
To obtain the 3′UTR cDNA of TPF1 and sAH (TPF1-
8994 and sAH-8994, respectively), cDNA was synthe-
sized with the XR58R primer, and then amplified by
PCR with the HC8939F and XR58R primers. The
terminus of the 3′UTR cDNA was obtained by 3′RACE.
Poly (A) tails were added to the total RNA in the serum
samples from patients TPF1 and sAH using the Poly (A)
Tailing Kit (Ambion) according to the manufacturer’s
instructions. HCV cDNA was synthesized with the dT-
Adp primer and then amplified by PCR with the 3UTR-
1 F and Adp primers. A second-round PCR was carried
out with primers XR58F and Adp, and then cloned
(TPF1-3′UTR and sAH-3′UTR). The primers used for
this study are shown in Additional file 1: Table S1.
Plasmid construction
In order to construct full-length HCV plasmids, PCR was
carried out with the primers 3′UTRcla and RP1xba, using
two PCR products, TPF1-3′UTR and sAH-3′UTR, as the
template, and the resulting cDNA clones were named
TPF1-3′UTRxba and sAH-5′UTRxba, respectively. Based
on the consensus sequence of TPF1, we assembled full-
length HCV cDNAs containing fragments TPF1-0007,
−0153, −4893, −8994, and −3′UTRxba, and the resulting
construct was named TPF1con. Another full-length HCV
cDNA, sAHcon, was also constructed using fragments
sAH-0007, −0153, −4893, −8994, and −3′UTRxba. The
cDNA encoding TPF1con and sAHcon was inserted
downstream of the T7 RNA promoter in pBluescript
SKII(+) (Agilent Technologies) to construct TPF1 (DDBJ/
EMBL/GenBank accession number LC011927) and sAH
(accession number LC011930), respectively. The TPF1
subgenomic replicon (rep_TPF1) and the sAH subge-
nomic replicon (rep_sAH) constructs were obtained by
replacing the regions encoding the structural proteins and
the NS2 protein with the sequences encoding neomycin
phosphotransferase (Neo) from a UAS-probe plasmid [36]
and the encephalomyocarditis virus (EMCV) IRES as
described previously [11].
Subgenomic replicon assay
XbaI-linearized plasmids encoding the TPF1 and sAH
replicons were in vitro-transcribed by T7 RNA polymer-
ase with the MEGAscript T7 kit (Ambion). The synthe-
sized replicon RNAs were purified according to the
manufacturer’s instructions and then electroporated into
Huh7 cells. In brief, 10 μg of replicon RNA was mixed
with 4 × 106 Huh7 cells in a 4-mm cuvette and then
pulsed at 250 V and 950 μF using Gene Pulser (Bio-Rad).
Replicon RNA-transfected cells were suspended in 8 mL
of complete DMEM culture medium and transferred into
a 100-mm culture dish (Iwaki). After 24 h of incubation,
G418 (Neomycin) was added to the culture medium (at
0.25–1 mg/mL). The medium was changed every 4 days,
and 20 days after electroporation, the surviving cell clones
were stained with PhastGel blue R (Sigma-Aldrich) or
cloned and expanded by growth in individual plates.
Sequence analysis of G418-resistant cells
Total RNA was extracted from the cloned G418-resistant
cells using the High Pure RNA Isolation kit (Roche)
according to the manufacturer’s instructions, and the
cDNAs of the replicon RNA were synthesized with the
XR58R primer. PCR amplification was performed with the
EMCV-S1 and 1b9405R primers. The sequence of each
recovered replicon, rep_TPF1 and rep_sAH, was deter-
mined. Plasmids for replicons rep_TPF1-4B and rep_sAH-
N3.5 containing the adaptive mutations were generated by
site-directed mutagenesis of the original constructs, which
were identified in the recovered replicons, using the Quick
Mutagenesis kit (Stratagene) according to the manufac-
turer’s instructions.
Construction of full-length HCV RNA
The full-length HCV construct TPF1-4B (accession num-
ber LC011928) was developed by replacing the SfiI frag-
ment with the corresponding fragment from rep_TPF1-
4B, containing the cell culture adaptive mutations in
NS4B (Q93L and E255K). Similarly, sAH-N3.5 (accession
number LC011931) was constructed by replacing the
BsrGI–SfiI fragment of rep_sAH-4B, which contains two
cell culture adaptive mutations in NS3 (T261K) and
NS5A (S232R). As a control, a replication-incompetent,
full-length HCV construct (TPF1-ΔGDD) was created by
an in-frame deletion of the polymerase active-site motif
GDD in the NS5B polymerase in TPF1-4B. Each mutation
and deletion was confirmed by DNA sequencing.
Quantification of the HCV core antigen
Core antigen levels were measured by sandwich enzyme
immunoassay (EIA) as described previously [33, 37]. To
quantify the core antigens in the culture medium and
cell lysate, these samples were diluted to the negative
control serum before pretreatment.
Quantification of HCV RNA by RT-PCR
HCV RNA was recovered from the culture media and cell
lysates using the High Pure Viral RNA kit (Roche) and the
High Pure RNA isolation kit (Roche), respectively. For
quantitative (q)RT-PCR analysis to detect the 5′UTR, HCV
RNA was reverse-transcribed and amplified using the
QuantiTect One-Step RT-PCR kit (QIAGEN) with primers
chiba-S and chiba-AS, as described previously [33].
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Establishment of cured Huh7 cells by IFN treatment
Huh7 cells containing replicon RNA (rep_TPF1-4B)
carrying adaptive mutations were cultured with human
recombinant IFN-αA/D (1000 IU/mL; R&D Systems) in
the absence of G418. After 3–4 days, 60 %-confluent
monolayers were trypsinized, plated, and cultured for
24 h before the addition of IFN-αA/D. After 4 weeks of
IFN treatment, the absence of HCV RNA was confirmed
from the results of a qRT-PCR assay and sensitivity to
G418. The cured cells were named ALS32.50 cells.
Full-length HCV RNA transfection
Full-length HCV RNAs were transcribed in vitro and
electroporated into cells as described above. In brief,
10 μg of in vitro-synthesized HCV RNA was mixed with
4 × 106 cells and transfected into Huh7 or ALS32.50
cells. Cells were seeded into 6-well plates for HCV RNA
and core Ag analyses. Virus harvests were clarified by
low-speed centrifugation and passed through a 0.45-μm
filter, and frozen at −80 °C.
Sucrose density gradient analysis of virus particles
The culture medium was harvested for sucrose density
gradient analysis 4 days after transfection of the full-
length HCV RNA. Collected culture media were cleared
by low-speed centrifugation, and passed through a 0.45-
μm filter. Filtered culture media were concentrated 30-
fold using an Amicon Ultra-15 device (Molecular cut-off:
1 × 105 Da; Millipore). Concentrated culture media with
or without NP-40 pretreatment were layered onto a step-
wise sucrose gradient (10–60 %, wt/vol) and centrifuged
for 16 h in a SW50.1 rotor (Beckman) at 40,000 rpm with
RNase A at 4 °C. After centrifugation, about 20 fractions
were collected. The HCV RNA and core antigen levels in
each fraction were determined by sandwich EIA and qRT-
PCR, as described above.
Infectivity assays
Huh7 and ALS32.50 cells were seeded at 1.6 × 104 cells/
well in 48-well plates (Iwaki), or at 2.0 × 104 cells/well in
collagen-coated 8-well chamber slides (Iwaki) for 24 h
before inoculation with 100 μL of filtered culture
medium. The amount of core antigen in inoculated cells
was determined by sandwich EIA, and the cells were
tested for the presence of intracellular core antigen by
indirect immunofluorescence analysis at 96 h post-infection
(p.i.), as described below. Clusters of infected cells, identi-
fied by staining for core antigen, were considered as a single
infectious focus, and virus titers were calculated accordingly
in terms of FFU (focus-forming unit)/mL.
Indirect immunofluorescence
Cells were fixed with methanol (99.8 %) at −20 °C for
15 min, and then stained with an anti-core monoclonal
antibody (5E3) [38] at 1 μg/mL, followed by extensive
washing and staining with an anti-mouse IgG labeled
with AlexaFlour594 (2 μg/mL; Molecular Probes). Nuclei
were counterstained with DAPI (Molecular Probes), and
the slides were examined with a Zeiss Axiovert 200 M
fluorescence microscope.
Construction of full-length chimeric genomes
To construct a full-length sAH-N3.5/AgeBsr chimeric
plasmid, the 5′UTR-NS2 sequences in sAH-N3.5 were
replaced with the corresponding segments in the AgeI
and BsrGI sites in TPF1-4B. A similar strategy was used
to construct sAH-N3.5/BsrXba (NS3-3′UTR), sAH-N3.5/
AgeBbv (5′UTR-E2), sAH-N3.5/BbvBsr (E2-p7), sAH-
N3.5/XmaBsr (NS2), sAH-N3.5/BbvNsi (p7-NS2aa114),
and sAH-N3.5/NsiBsr (C-terminal half of NS2). Variants
containing the three different amino acids sequences
(Q148R, M170T, and S189L) were identified by comparing
the C-terminal halves of the NS2 sequences in TPF1-4B
and sAH-N3.5. Three different amino acid sequences were
inserted into the TPF1-4B genome using site-directed
mutagenesis to create the TPF1-Q148R, TPF1-M170T
(accession number LC011929), and TPF1-S189L con-
structs, respectively. Variant constructs were verified by
DNA sequencing.
Neutralization assay
ALS32.50 cells were infected with culture medium sup-
plemented with an anti-CD81 monoclonal antibody
(clone JS-81; BD Pharmingen) [5] and a control mono-
clonal antibody (anti-HBcrAg; clone HB61) [39], or 2′C-
methyladenosine (2′CMeA; Carbosynth) at final concen-
trations of 10 μg/mL (anti-CD81 and anti-HBsAg) or
5 μM (2′CMeA). Six hours after inoculation, the cells
were inoculated into complete DMEM culture medium.
Cultures were incubated for 96 h, and then the cells
were harvested and lysed for sandwich EIA and qRT-PCR.
Results
Establishment of genotype 1b HCV subgenomic replicons
from Two patients with different symptoms
To identify the regions in the genotype 1b HCV genome
that govern the efficiency of HCVcc replication, we iso-
lated HCV genomes with distinctive phenotypes from
two patients with different clinical symptoms, including
the efficacy of IFN therapy (Table 1): patient TPF1 had
recurrent fulminant hepatitis after liver transplantation,
and patient sAH had acute hepatitis. The titers of the
HCV specimens collected from patients TPF1 and sAH
were 4 × 107 copies/mL and 1.3 × 105 copies/mL, re-
spectively. Subgenomic replicons carrying the consensus
sequences of TPF1 and sAH were constructed and sub-
sequently transfected into Huh7 (JCRB0403) cells, as
previously described [11]. The sAH replicon produced
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2.2 ± 0.7 G418-resistant colonies per microgram of RNA,
whereas the TPF1 replicon yielded a single colony when
more than 100 μg of RNA was transfected (<0.01 colony
per microgram of RNA) (Fig. 1a). We recovered subge-
nomic RNA from cells harboring the replicons and de-
termined their nucleotide sequences. The recovered
replicons, which we termed rep-sAH-N3.5 and rep-
TPF1-4B, each carried two mutations: T261K (in NS3)
and S232R (in NS5A) in rep-sAH-N3.5, and Q93L and
E255K (both in NS4B) in rep-TPF1-4B. Both replicons
exhibited significantly high colony formation efficiencies
compared to that of the original construct (Fig. 1b).
Therefore, these mutations were considered to be adap-
tive mutations that allowed for efficient replication in
Huh7 cells. The positions of the mutations in rep-sAH-
N3.5 were reported previously [12, 15]; however, those
in rep-TPF1-4B were novel.
Distinctive infectious virus-forming abilities between the
Two genotype 1b HCV genomic RNAs
The full-length HCV genomic RNAs TPF1-4B and sAH-
N3.5 were constructed to harbor the adaptive mutations
found in the recovered subgenomic replicons (Fig. 1c).
We transfected these full-length genomic RNAs along
with an RNA replication-defective mutant of TPF-4B
(TPF1-ΔGDD), in which the RdRp motif (Gly-Asp-Asp)
in the NS5B polymerase active site was deleted, into
naïve Huh7 cells, and then quantitated the intracellular
HCV RNA and core antigens at several time points after
transfection. The levels of RNA and core antigens in the
cells transfected with TPF1-4B or sAH-N3.5 RNAs in-
creased by 72 h post-transfection (p.t.), whereas those in
cells transfected with TPF1-ΔGDD RNA decreased
(Fig. 1d, e), suggesting that the increase in HCV RNA
and core Ag levels occurred in an NS5B RNA
polymerase-dependent manner. Although rep-sAH-N3.5
exhibited approximately 7-times higher colony-forming
activity than that of rep-TPF1-4B, the HCV RNA and
core antigen levels in cells transfected with TPF1-4B or
sAH-N3.5 RNAs were similar.
The level of HCV core Ag in the culture medium ob-
tained from cells transfected with TPF1-4B RNA was
over 18-times higher than that in the medium obtained
from cells transfected with sAH-N3.5 RNA (Fig. 1f ) at
72 h p.t., suggesting a difference in the production of
virus particles between these two HCV RNAs. We
fractionated the HCV core antigens and RNA in these
culture media by sucrose density gradient ultracentri-
fugation. The peaks of both the core Ag and HCV
RNA from cells transfected with TPF1-4B RNA mi-
grated at the same density of 1.17 g/mL (Fig. 2a,
upper). Treatment of the samples with NP40 resulted
in a peak shift for both the core Ag and RNA to a
density of 1.25 g/mL. These observed densities of HCV
RNA and core Ag were similar to those previously de-
scribed for virus particles and capsids in HCVcc [5].
These data suggested that TPF1-4B could produce
HCV particles in transfected cells.
In contrast, HCV RNA and the core antigen from
the culture medium of sAH-N3.5-transfected cells
fractionated differently (Fig. 2b, upper). The decreased
amount of HCV RNA and the lack of a peak shift for
the core Ag following NP-40 treatment suggested that
most of the sAH-N3.5 genomic RNA was not packaged
in capsids with core Ag, and thus did not form virus
particles.
We examined the infectivity of the virus particles
produced by monitoring the production of HCV core Ag
in naïve Huh7 cells inoculated with media harvested
from cells transfected with TPF1-4B or sAH-N3.5 RNA.
The amount of HCV core Ag in cells inoculated with
the culture medium from TPF1-4B RNA-transfected
cells increased at 72 h post-infection (p.i.), whereas that
in cells inoculated with the culture medium from sAH-
N3.5 RNA-transfected cells did not increase (Fig. 2c).
The number of HCV core Ag-positive cells (determined
by a focus-forming assay [FFA]; Fig. 2d) was more than
10-times higher in the wells inoculated with the 72 h
p.t. culture medium than in wells inoculated with the
48 h p.t. culture medium collected from cells trans-
fected with TPF1-4B RNA. The lag time between the
continuous secretion of core Ag into the culture
medium and the abrupt increase in the number of
focus-forming units (FFU; Fig. 1f ) suggested that infec-
tious virus was produced after the accumulation of core
Ag. These data indicated that TPF1-4B RNA could
effectively replicate and produce infectious virus in the
naïve Huh7 cells.







Response of IFN treatmenta NR SVR
HCV RNA in serum (copies/mL) 4.0 × 107 1.3 × 105
Core 70/91b Mutant/Wild Wild/Wild
ISDR (a.a.2209–2248)c Wild Wild
IRRDR (a.a.2234–2379)d 5 5
Subgenomee Yes No
aNR non responder, SVR sustaind virologic response
bPretreatment predictor of poor virologic response [51]
cIFN sensitivity-determining region [52]
dIFN/RBV resistance-determining region [53]
eLarge in-frame deletions of E1/E2 proteins in specimens of chronically infected
patients [33]
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Fig. 1 (See legend on next page.)
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A sequence variant in NS2 potentiates infectious virus
formation
Variation in the efficiencies of subgenomic replicon
replication and infectious virus production of the two
different genomic RNAs suggested that some genomic
segments affect the replication of genotype 1b HCV
clones in the HCVcc. We investigated the segments
that affect replication by exchanging segments between
sAH-N3.5 and TPF1-4B (Fig. 3a). Introduction of a
core-NS2 segment of TPF1-4B into the sAH-N3.5 repli-
con resulted in approximately 3-fold higher core Ag
levels in the culture medium compared to that of the
native sAH-N3.5. However, the core Ag level of this
chimera was still 1/3 of that in the TPF1-4B medium,
suggesting that the replication machinery of sAH-N3.5
is responsible for the poor infectious virus production.
A genomic RNA, sAH-N3.5/AgeBsr, which carried the
structural regions (from the 5′UTR [AgeI] to the NS2)
of sAH-N3.5 and the nonstructural regions (from NS3
to the 3 UTR) of TPF1-4B, produced nearly 10-times
more core Ag in the culture medium of transfected cells
than the original construct (TPF1-4B) (Fig. 3a). Experi-
ments using sAH-N3.5/AgeBbv and sAH-N3.5/BbvBsr,
which carried portions of the sAH-N3.5 structural
regions, showed that the region spanning from p7 to
the end of NS2 strongly potentiated core Ag secretion,
with levels 14.5-times greater than that of the native
TPF1-4B RNA.
Among the cells transfected with the four HCV gen-
omic RNAs carrying smaller portions of the p7-NS2
segment, sAH-N3.5/NsiBsr-transfected cells secreted
the highest core Ag levels into the culture medium
(Fig. 3b, c). We performed an FFA using the 72-h p.t.
culture medium, and found that the culture medium of
AH-N3.5/NsiBsr-transfected cells produced 8-times
more foci than the medium of TPF1-4B-transfected
cells (Fig. 3c). These results indicate that the C-
terminal half of NS2 in sAH-N3.5 is responsible for
potentiating infectious virus formation in the TPF1-4B
genomic context.
There are three differences in the NS2 amino acid
sequences between TPF1-4B and sAH-N3.5: Q148R,
M170T, and S189L. We introduced each variant
individually into TPF1-4B and assessed the infectious
virus-forming activity of genomic RNAs carrying these
variants. The secretion of core Ag was increased slightly
in TPF1-Q148R and TPF1-S189L RNA-transfected cells
compared to that of wild-type TPF1-4B. However, the
secretion of the core Ag of TPF1-M170T was similar to
that of sAH-N3.5/NsiBsr (Fig. 3c). In addition, the 72-h
p.t. culture medium from cells transfected with TPF1-
M170T produced 7-times the foci produced by TPF1-4B
(Fig. 3c).
HCV genomic RNA carrying a variant in NS2 produced
infectious virus
To further analyze TPF1-M170T, we established
ALS32.50-cured cells derived from Huh7 cells harbor-
ing the TPF1-4B subgenomic replicon (see Methods).
ALS32.50 cells transfected with TPF1-M170T RNA se-
creted higher amounts of HCV RNA and core Ag into
the culture medium than cells transfected with TPF1-
4B RNA at 96 h p.t. (Table 2). It is noteworthy that
the ratio of core Ag to HCV RNA in the culture
medium of TPF1-M170T-transfected cells was lower
than that of TPF1-4B-transfected cells. Inoculation of
the culture medium recovered at 96 h p.t. showed that
approximately 37-times more foci were produced in
the TPF1-M170T culture medium than in the TPF1-4B
culture medium. Using ALS32.50-cured cells, we were
able to produce infectious virus particles more effi-
ciently than using naïve-Huh7 cells.
We carried out inhibitory assays using a CD81-specific
antibody and the NS5B polymerase inhibitor 2’CMeA
for infection with culture medium inoculation. Using the
CD81-specific antibody, we observed approximately
20-fold and 50-fold reductions of HCV RNA and HCV
core Ag, respectively, in cells inoculated with the 96 h
culture medium compared to cells transfected with
TPF1-M170T RNA. Similar reductions in HCV RNA
(10-fold) and core Ag (50-fold) were observed in cells
treated with 2C’MeA (Fig. 4). These data suggested that
the infectious virus produced by the cured cells trans-
fected with TPF1-M170T RNA infected the naïve cured
cells in a CD81-dependent manner, and replicated them-
selves using own NS5B polymerase.
(See figure on previous page.)
Fig. 1 Replication of TPF1 and sAH RNAs in transfected Huh7 cells. a Structure of the subgenomic replicon. b Huh7 cells were transfected with
the wild-type replicons (WT) or a replicon RNA carrying the adaptive mutations (Recovered). Numbers below the plates refer to colony-forming
units (CFU) per microgram of in vitro-transcribed replicon RNA. With the rep-TPF1 of WT replicons, ten independent transfections were performed.
With the rep-sAH of WT and adapted replicons, three independent transfections were performed. c The structures of the full-length HCV genomes
TPF1-4B and sAH-N3.5 are shown. Both full-length genomes carry the heterologous sequence (shaded area) derived from the highly adapted
subgenomic replicons, showing the location of the adaptive mutations. GDD is the active-site motif of NS5B polymerase. d–f Time course of
HCV RNA replication (d), core Ag expression (e), and core Ag secretion (f) in transfected Huh7 cells. Huh7 cells were electroporated with TPF1-4B
(□), sAH-N3.5 (△), and TPF1-ΔGDD (○) RNA transcripts. TPF1-ΔGDD contains a deletion of the polymerase active-site motif (GDD) in NS5B
polymerase. The HCV RNA and core Ag levels were measured by qRT-PCR and sandwich EIA at the indicated time points, respectively.
Results represent the mean of three independent experiments ± standard deviations
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Fig. 2 (See legend on next page.)
Mori et al. BMC Microbiology  (2016) 16:224 Page 8 of 13
Discussion
We developed an HCVcc from genotype 1b HCV cDNA
clones that were isolated from two patients with distinct-
ive symptoms and significantly different viral RNA titers.
We introduced several mutations and variants into the
HCVcc to increase the efficiency of viral replication, the
effects of which were sensitive to the genomic context.
The established HCVcc, TPF1-M170T, could infect naïve
cured Huh7 cells in a CD81-dependent manner, and
replicate itself using its RdRp, NS5B.
(See figure on previous page.)
Fig. 2 Characterization of TPF1-4B and sAH-N3.5 virus particles. a, b Concentrated culture medium collected from TPF1-4B (a) and sAH-N3.5 (b).
RNA-transfected cells were fractionated using a 10–60 % stepwise sucrose density gradient. HCV RNA and core Ag levels were measured by qRT-
PCR and sandwich EIA, respectively. Culture media after treatment with 0.2 % NP-40 prior to centrifugation were also analyzed (a, b lower panels).
c Comparison of the infectivity of the culture medium from TPF1-4B RNA- and sAH-N3.5 RNA-transfected Huh7 cells. Culture media at 72 h after
transfection were used to inoculate naïve Huh7 cells, and HCV core Ag levels were determined at 24, 48, 72 and 96 h after infection. d Time
course of infectious TPF1-4B virus released into the culture medium of RNA-transfected Huh7 cells, as measured by FFA. The insert shows the
HCV core Ag levels (red) detected by indirect immunofluorescence in cells infected with TPF1-4B viral particles at 72 h after transfection. The
nuclei were counterstained with DAPI (blue). Assays (D and E) were conducted two independent experiments, and results represent the mean
of three independent experiments ± standard deviations
Fig. 3 Viral particle production of chimeric sAH-N3.5/TPF1-4B virus. a Organization of full-length HCV constructs. Four sAH-N3.5/TPF1-4B clones
were developed by swapping regions of the TPF1-4B genome (from the core to NS2, NS3 to NS5B, the core to E2, and p7 to NS2 regions) with
the corresponding region of the sAH-N3.5 genome to create the sAH-N3.5/AgeBsr, /BsrXba, /AgeBbv, and /BbvBsr constructs, respectively. The
sAH-N3.5 genome sequences are shown in gray, and the TPF1-4B sequences are shown in white. Huh7 cells were transfected with the full-length
RNAs shown on the left, and the amounts of HCV core Ag were determined in the culture medium of cells at 72 h after transfection. b Organization
of full-length HCV constructs. Three sAH-N3.5/TPF1-4B clones were generated by swapping the regions NS2, p7 to NS2aa114, and the C-terminal half of
NS2 in the TPF1-4B genome with the corresponding regions of the sAH-N3.5 genome to create the sAH-N3.5/XmaBsr, /BbvNsi, and /NsiBsr constructs,
respectively. The positions of the three different amino acid variants (Q148R, M170T, and S189L) were confirmed by alignment of the C-terminal half of
the NS2 sequences from TPF1-4B and sAH-N3.5 (top row). Three different amino acids sequences were inserted into the TPF1-4B genome to create the
TPF1-Q148R, TPF1-M170T, and TPF1-S189L constructs. c In order to compare their ability to produce viral particles, we collected the culture medium
of cells at 72 h after transfection and quantified infectivity by FFA. All assays were conducted two independent experiments, and data are represented
by an average
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rep-sAH-N3.5, which was derived from HCV cDNA of
a patient with acute hepatitis, carried previously de-
scribed adaptive mutations in NS3 [12, 15]. When these
mutations were introduced into the full-length sAH-
N3.5 HCV genomic RNA, the RNA efficiently replicated
in Huh7-transfected cells. However, cells transfected
with this viral RNA in its original full-length context
barely produced any infectious particles, as the other
genotype 1b clone, Con1, carrying adaptive mutations in
NS3 and NS5 [31]. Though the colony forming effi-
ciency of rep-TFP1-4B, which carries newly identified
adaptive mutations in NS4B, was lower than that of
rep-sAH-N3.5, TFP1-4B can produce infectious viral
particles. Taking into account that Con1 genome carry-
ing the adaptive mutations in NS4B (K1846T) can pro-
duce infectious particles with moderate interference,
NS4B should have an impact on virus particle formation,
in addition to the known NS4B function serving a
scaffold for the viral replicase complex formation to
regulate HCV genome replication [1, 40–43].
Surprisingly, the 5′-segment of rep-sAH-N3.5 could
potentiate infectious virus formation in combination
with 3′-half genomic segments from rep-TFP1-4B RNA
carrying the adaptive mutations in NS4B not with that
from rep-sAH-N3.5. In the 5′-half of the sAH-N3.5 gen-
omic RNA, we determined that an amino acid sequence
variant at the 170th position in NS2 is the variant that
potentiated infectious virus formation by TPF-4B. At
this position, methionine is a major variant, and M170T,
which was the responsive variant in the sAH HCV
genome, is rare among HCV genomes (Los Alamos HCV
sequence database). The crystallographic analysis indi-
cated that M170 is located in the crossover region of the
NS2-protease dimer [44]. Alanine scanning of NS2
showed that the M170A variant exhibited increased
dimer formation in vitro and that the JFH clone carrying
M170A showed decreased infectivity in naïve Huh7.5
cells. However, this mutation had no significant effect on
the infectivity of the J6-H77NS2-JFH chimeric HCV
genome. These data indicate that the amino acid at
position 170 of NS2 affects the infectivity of HCVcc in a
genomic context-dependent manner.
The ratio of the core Ag to the HCV RNA levels in
the culture medium of TPF1-M170T-infected cells was
lower than that of TPF1-4B-infected cells, which sug-
gested that M170T improved core protein assembly
into infectious virus. Assembly deficiencies caused by
mutations in core proteins have been reported to be
Table 2 The ratio of HCV core Ag to HCV RNA and the infectivity of culture medium recovered at 96-h p.t
Time after transfection (96 hr)
Core Ag RNA Core Ag/RNA FFU Specific infectiveity
(fmol/L) (molecules/mL) (copies/mL) (molecules/copy) (/mL) (FFU/mL)
TPF1-4B 5892.4 3.5E + 09 7.2E + 05 4926.7 35 4.9E-05
TPF1-M170T 42742.7 2.6E + 10 1.1E + 07 2427.5 1300 1.2E-04
Fig. 4 Neutralization of the cell culture by treatment with a CD81-specific antibody. ALS32.50 cells were inoculated with culture medium containing
approximately 1300 FFU/mL in the presence of a CD81-specific antibody (anti-CD81, gray bar), polymerase inhibitor (2′CMeA, black bar), or a control
antibody (CTRL, white bar), and were incubated for 96 h. Inoculated cells were analyzed by qRT-PCR and sandwich EIA. Values obtained with FFU in
the presence of CTRL were set to 100 %. All assays were conducted two independent experiments, and data are represented by an average
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compensated by mutations in NS3, p7, and NS2 [24].
Among these mutations, the positions of compensatory
mutations in NS2 are located in the transmembrane
domain. Mutations in the core, envelope proteins, p7,
and NS5A, which abolish viral assembly, altered the
subcellular localization of NS2 proteins [45]. The sub-
cellular localization of NS2 is determined by its trans-
membrane domain. In addition, the second α-helix of
the protease domain functions in the interaction
between NS2 and the membrane [46]. These data sug-
gested that M170A may affect the molecular interac-
tions of HCV proteins, thereby changing the efficiency
of capsid assembly.
Cells transfected with TPF1-4B continuously secreted
core Ag into the culture medium until 96-h p.t. How-
ever, the infectivity of the medium abruptly increased at
72 h, suggesting that the accumulation of HCV proteins
or induced host factors might be essential for infectious
virus formation. Using cured cells, the infectivity of
HCVcc was observed in the 24-h culture medium trans-
fected with TPF1-M, and it increased through to 96 h
p.t. This could be an importance of the host factor for
assembly of HCVcc capsids, as previously identified in
Huh7.5 cells [47, 48]. Although ALS32.50 was estab-
lished by the same method as Huh7.5, another host fac-
tor might contribute the infectivity genotype 1b HCV in
ASL32.50, because of the decreased infectivity of the
JFH clone carrying M170A in naïve Huh7.5 cells [44].
Huh7.5 cells transfected with RNA established in this
study could provide insight into a novel host factor for
genotype 1b HCVcc.
Prior to the present study, no HCVcc carrying a full
genotype 1b genome had been reported. Although the
full-length HCV genomic RNA could replicate in cul-
tured cells and produce infectious virus as previously
reported [31, 49, 50], the infection efficiency was insuf-
ficient for autonomous virus propagation in cultured
cells, even when the production efficiency increased
with the inclusion of adaptive mutations. Therefore,
the infectivity of the virus particles must be further
improved to develop a robust HCVcc of genotype 1b.
We acknowledge that the efficiency of virus replication
of the present HCVcc is quite low compared to the
HCVcc containing JFH-1 genomic segments. However,
our system will nevertheless provide insight into
genotype 1b HCV, which is the second major genotype
of HCV.
Conclusions
In conclusions, we established a novel HCVcc genotype
1b in Huh7 cells by introducing an amino acids variant
in NS2 and the mutations in NS4 in HCV genomic RNA
isolated from a patient with fuluminant HCV after liver
transplantation.
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